Internal and Environmental Predictors of Physician Practice Use of Screening and Medications for Opioid Use Disorders

Overview

Journal Med Care Res Rev

Specialty Health Services

Date 2023 Apr 10

PMID 37036056

Authors

Chris Miller-Rosales

Susan H Busch

Ellen R Meara

Ashleigh King

Thomas A DAunno

Carrie H Colla

Affiliations

Soon will be listed here.

Abstract

Medications for opioid use disorder (MOUD) remain highly inaccessible despite demonstrated effectiveness. We examine the extent of screening for opioid use and availability of MOUD in a national cross-section of multi-physician primary care and multispecialty practices. Drawing on an existing framework to characterize the internal and environmental context, we assess socio-technical, organizational-managerial, market-based, and state-regulation factors associated with the use of opioid screening and offering of MOUD in a practice. A total of 26.2% of practices offered MOUD, while 69.4% of practices screened for opioid use. Having advanced health information technology functionality was positively associated with both screening for opioid use and offering MOUD in a practice, while access to on-site behavioral clinicians was positively associated with offering MOUD in adjusted models. These results suggest that improving access to information and expertise may enable physician practices to respond more effectively to the nation's ongoing opioid epidemic.

Citing Articles

Behavioral health treatment delivery by social workers in accountable care organizations.

Miller-Rosales C, Meara E, Murphey J, Dasgupta A, Lewinson T Soc Work Health Care. 2024; 63(8-10):600-622.

PMID: 39576745 PMC: 11666320. DOI: 10.1080/00981389.2024.2427750.

Optimizing Patient Engagement in Treatment for Opioid Use Disorder: Primary Care Team Perspectives on Influencing Factors.

Austin E, Chen J, Soyer E, Idrisov B, Briggs E, Ferro L J Gen Intern Med. 2024; 39(16):3196-3204.

PMID: 39073482 PMC: 11618257. DOI: 10.1007/s11606-024-08963-9.

References

DAunno T, Friedmann P, Chen Q, Wilson D . Integration of Substance Abuse Treatment Organizations into Accountable Care Organizations: Results from a National Survey. J Health Polit Policy Law. 2015; 40(4):797-819. PMC: 4704856. DOI: 10.1215/03616878-3150062. View

Frehn J, Brewster A, Shortell S, Rodriguez H . Comparing health care system and physician practice influences on social risk screening. Health Care Manage Rev. 2021; 47(1):E1-E10. PMC: 9646465. DOI: 10.1097/HMR.0000000000000309. View

Austin E, Briggs E, Ferro L, Barry P, Heald A, Curran G . Integrating Routine Screening for Opioid Use Disorder into Primary Care Settings: Experiences from a National Cohort of Clinics. J Gen Intern Med. 2022; 38(2):332-340. PMC: 9132563. DOI: 10.1007/s11606-022-07675-2. View

Spetz J, Hailer L, Gay C, Tierney M, Schmidt L, Phoenix B . Changes in US Clinician Waivers to Prescribe Buprenorphine Management for Opioid Use Disorder During the COVID-19 Pandemic and After Relaxation of Training Requirements. JAMA Netw Open. 2022; 5(5):e225996. PMC: 9099425. DOI: 10.1001/jamanetworkopen.2022.5996. View

Walley A, Alperen J, Cheng D, Botticelli M, Castro-Donlan C, Samet J . Office-based management of opioid dependence with buprenorphine: clinical practices and barriers. J Gen Intern Med. 2008; 23(9):1393-8. PMC: 2518016. DOI: 10.1007/s11606-008-0686-x. View

Lewis V, Colla C, Tierney K, Van Citters A, Fisher E, Meara E . Few ACOs pursue innovative models that integrate care for mental illness and substance abuse with primary care. Health Aff (Millwood). 2014; 33(10):1808-16. DOI: 10.1377/hlthaff.2014.0353. View

Andrilla C, Jones K, Patterson D . Prescribing Practices of Nurse Practitioners and Physician Assistants Waivered to Prescribe Buprenorphine and the Barriers They Experience Prescribing Buprenorphine. J Rural Health. 2019; 36(2):187-195. DOI: 10.1111/jrh.12404. View

Saloner B, Andraka Christou B, Gordon A, Stein B . It will end in tiers: A strategy to include "dabblers" in the buprenorphine workforce after the X-waiver. Subst Abus. 2021; 42(2):153-157. PMC: 8667660. DOI: 10.1080/08897077.2021.1903659. View

Haffajee R, Lin L, Bohnert A, Goldstick J . Characteristics of US Counties With High Opioid Overdose Mortality and Low Capacity to Deliver Medications for Opioid Use Disorder. JAMA Netw Open. 2019; 2(6):e196373. PMC: 6604101. DOI: 10.1001/jamanetworkopen.2019.6373. View

10.

Volkow N . Medications for opioid use disorder: bridging the gap in care. Lancet. 2017; 391(10118):285-287. DOI: 10.1016/S0140-6736(17)32893-3. View

11.

Robinson R, Gatchel R, POLATIN P, Deschner M, Noe C, Gajraj N . Screening for problematic prescription opioid use. Clin J Pain. 2001; 17(3):220-8. DOI: 10.1097/00002508-200109000-00006. View

12.

Rosenblum A, Cleland C, Fong C, Kayman D, Tempalski B, Parrino M . Distance traveled and cross-state commuting to opioid treatment programs in the United States. J Environ Public Health. 2011; 2011:948789. PMC: 3136171. DOI: 10.1155/2011/948789. View

13.

Jones C, McCance-Katz E . Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder. Addiction. 2018; 114(3):471-482. DOI: 10.1111/add.14436. View

14.

Cheng H, McGovern M, Garneau H, Hurley B, Fisher T, Copeland M . Expanding access to medications for opioid use disorder in primary care clinics: an evaluation of common implementation strategies and outcomes. Implement Sci Commun. 2022; 3(1):72. PMC: 9258188. DOI: 10.1186/s43058-022-00306-1. View

15.

Madras B, Ahmad N, Wen J, Sharfstein J . Improving Access to Evidence-Based Medical Treatment for Opioid Use Disorder: Strategies to Address Key Barriers within the Treatment System. NAM Perspect. 2022; 2020. PMC: 8916813. DOI: 10.31478/202004b. View

16.

Chou R, Fanciullo G, Fine P, Adler J, Ballantyne J, Davies P . Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009; 10(2):113-30. PMC: 4043401. DOI: 10.1016/j.jpain.2008.10.008. View

17.

Fiellin D, Pantalon M, Chawarski M, Moore B, Sullivan L, OConnor P . Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med. 2006; 355(4):365-74. DOI: 10.1056/NEJMoa055255. View

18.

Lewis V, Spivack S, Murray G, Rodriguez H . FQHC Designation and Safety Net Patient Revenue Associated with Primary Care Practice Capabilities for Access and Quality. J Gen Intern Med. 2021; 36(10):2922-2928. PMC: 8481458. DOI: 10.1007/s11606-021-06746-0. View

19.

Jamison R, Scanlan E, Matthews M, Jurcik D, Ross E . Attitudes of Primary Care Practitioners in Managing Chronic Pain Patients Prescribed Opioids for Pain: A Prospective Longitudinal Controlled Trial. Pain Med. 2015; 17(1):99-113. DOI: 10.1111/pme.12871. View

20.

Cher B, Morden N, Meara E . Medicaid Expansion and Prescription Trends: Opioids, Addiction Therapies, and Other Drugs. Med Care. 2019; 57(3):208-212. PMC: 6375792. DOI: 10.1097/MLR.0000000000001054. View